Although PD-L1 expression is currently a predictor of efficacy for anti-PD-1/PD-L1 antibodies, the most commonly used ICIs for lung cancer, we did not investigate changes in PD-1 expression following MDRVV administration. The gene discussed is PDCD1; the disease is lung cancer.